Analytical Data
-
Gene name
HLA-A*02:01&B2M&p53(HMTEVVRHC) Monomer
- Application
-
Alternative Names
HLA-A*0201 & B2M & p53 (HMTEVVRHC)
-
Species
Human
-
Source
HEK293
-
Tag
C-Avi;C-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
AAA59606.1 (G25-I308)&P61769
-
Expression Region
AAA59606.1 (G25-I308)&P61769 (I21-M119)&HMTEVVRHC
-
Molecular Weight
58-65 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The study of the HLA-A*02:01/B2M/p53 (HMTEVVRHC) monomeric recombinant protein is crucial in the field of immunology and cancer research. HLA-A*02:01 is one of the most common human leukocyte antigen (HLA) class I molecules, playing a pivotal role in presenting endogenous peptides, such as tumor-associated antigens, to CD8+ T cytotoxic cells. The p53 protein, known as a tumor suppressor, is frequently mutated in various cancers, leading to the generation of unique epitopes that can elicit immune responses. The specific peptide HMTEVVRHC, derived from the p53 protein, is recognized by HLA-A*02:01, making it an ideal candidate for immunotherapeutic approaches aimed at targeting p53-mutated tumors. By creating a recombinant protein that comprises HLA-A*02:01, beta-2-microglobulin (B2M), and the specific p53-derived peptide, researchers can investigate the structural and functional characteristics of the HLA-peptide complex. This can enhance our understanding of T cell recognition mechanisms and help in the development of peptide-based vaccines or immunotherapies designed to activate the immune system against cancers. Additionally, this research can contribute to identifying biomarkers for tumor immunogenicity, ultimately leading to personalized cancer treatment strategies that are more effective and tailored to individual patients.
